Preclinical Imaging (In-VIVO) Market Size, Industry
Analysis Report, Regional Outlook from 2017 to 2024.:
Global Market Insights Inc.
Preclinical Imaging (In-VIVO) Market size will witness a substantial growth in the
forecast period with rising investments for monitoring treatment response for early
disease diagnosis along with cancer cell detection, bio distribution and drug target.
Preclinical imaging (In-VIVO) is gradually used across several drug development
processes, with applications ranging from compound optimization, to target
identification studies. The use of preclinical imaging (In-VIVO) across several domains
will boost the industry growth.
Technological innovations such as combination of high resolution MRI with other
imaging modalities should propel industry growth. The new imaging systems
incorporate novel technologies, electronics, detectors, reconstruction algorithms and
innovative software system modelling. Increasing amount of funding and public-private
initiatives to discover the underlying mechanisms of diabetes, immunological,
cardiovascular, and neurodegenerative diseases is likely to boost the preclinical imaging
(In-VIVO) market growth. High product price leading to decreased adoption rates
among academic institutions and limited application of each modality can negatively
impact the growth.
Oncology is likely to account for highest revenue share during the forecast period. It
remains a foremost focus of the pharmaceutical companies, and companies are heavily
investing to move biologics and drugs from clinical development phases to regulatory
approval. Anatomical imaging, neurology and cardiology are likely to grow at healthy
rate by 2024. By end use, research organizations segment is poised to account for major
revenue share due to wide usage in research organizations to conduct numerous
studies. Increasing purchasing power of the end user in the developing and
underdeveloped economies will collectively contribute towards industry growth.
U.S. will dominate the global revenue share owing to presence of established
infrastructure and major public and private companies. European preclinical imaging
(In-VIVO) market held the second largest revenue share in 2016. Increasing R&D and
favorable growth opportunities for players in the region will drive the region growth.
Asia Pacific preclinical imaging (In-VIVO) market is expected to rise at comparatively
faster rate in comparison to developed regions. India is likely to exhibit the highest
CAGR by 2024 with growing number of research and pharmaceutical organizations for
disease diagnosis.
1 | Page